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2767with the LDL-lowering effect, but that this relation-
ship is driven by the total daily dose of nuts, rather
than by differences in phytosterol content between
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2005;53:9436–45.When to Call It Severe
Mitral Regurgitation?I read with great interest the article by Grayburn et al.
(1), which deﬁned “severe” secondary mitral regur-
gitation (MR). The investigators did a great job of
explaining the mechanism and application of new
guidelines in the evaluation of MR. The investi-
gators proposed that classiﬁcation of a patient with
severe secondary MR should be deferred until
guideline-directed medical therapy or interventions
are optimized.
Current guidelines for valvular heart disease deﬁne
the class of valvular heart disease by echocardio-
graphic data and symptoms, asymptomatic severe MR(stage C), and symptomatic severe MR (stage D) (2).
However, the severity of MR is primarily based on
the echocardiographic ﬁndings, including color
Doppler, vena contracta, effective regurgitant oriﬁce,
and regurgitant volume and/or fraction. It is well
known that the severity of MR is dependent on the
loading conditions (blood pressure and heart rate),
and that there may be disparities among various pa-
rameters for the assessment of severity. The echo-
cardiologist reading the study may not have any
knowledge about the optimization of the medical
therapy, and may ﬁnd it difﬁcult not to describe a
patient with severe MR if the patient meets the
echocardiographic diagnostic criteria for severe MR.
It seems more logical to say that the decision to
recommend surgical or other invasive procedures
should be deferred until the guideline-directed ther-
apy has been optimized and the severity of MR sub-
sequently reassessed. However, more research is
needed in this area to further deﬁne the duration of
optimal therapy.*Gyanendra K. Sharma, MD
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Mitral Regurgitation?As stated in our review article, functional mitral
regurgitation (MR) is notoriously dynamic and may
change in severity depending on loading conditions
(1). Dr. Sharma correctly points out that echocardi-
ographers may be unaware of whether a given patient
is appropriately treated or not, and therefore, they
must base severity on the echocardiographic ﬁndings
alone. We agree with Dr. Sharma that “the decision to
recommend surgical or other invasive procedures
should be deferred until the guideline-directed
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2768therapy has been optimized and the severity of MR
subsequently reassessed.” This is precisely the point
we attempted to make, and we thank Dr. Sharma
for allowing us to clarify it. The recent American
Heart Association/American College of Cardiology
Guidelines on Valvular Heart Disease emphasize
disease staging, in which stage C is asymptomatic
severe MR and stage D is symptomatic severe MR (2).
We believe that stage C or D functional MR should
not be deﬁned by a single echocardiogram at
a given point in time, but rather by persistent
evidence of severe MR despite optimization of med-
ical therapy, cardiac resynchronization, and revas-
cularization (3). Even then, there is no convincing
evidence that surgical or percutaneous mitral
valve intervention improves survival (2,3). The eval-
uation of severe functional MR and the decision
to intervene is quite complex, with an emerging
consensus that it should be made by a multidisci-
plinary heart team (1–4).*Paul A. Grayburn, MD
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Intensity Statin Therapy
After Hospitalization for
Coronary Heart Disease
A Cause for Concern,
But a Few Words of CautionWe read with interest the paper by Rosenson et al. (1),
who performed a retrospective analysis showing that
only a “disappointing” 27% in a 5% random sample of
Medicare patients 65 to 74 years of age hospitalized
for acute myocardial infarction or revascularization
from 2007 to 2009 had been prescribed high-intensity
statins. Stricter adherence to the 2013 American Heart
Association/American College of Cardiology (AHA/
ACC) Guidelines was called for in the accompanying
editorial comment. We would like to offer some
words of caution.
Mounting evidence for harms (e.g., rhabdomyol-
ysis, diabetes, acute renal failure) (2) associated with
high-intensity statins published in the data and
treatment at our institution of 3 recent consecutive
cases of severe rhabdomyolysis (2 lethal and
1 severely debilitating, resulting in ﬂaccid quadri-
plegia) in patients treated with high-intensity statins
according to the new AHA/ACC guidelines prompted
us to review the main evidence behind those recom-
mendations, with respect to beneﬁts on “hard” end-
points such as all-cause mortality or cardiovascular
mortality.
In chronic stable coronary heart disease (CHD), 3 ma-
jor secondary prevention trials were identiﬁed: TNT
(Treat to New Targets), IDEAL (Incremental Decrease in
End Points Through Aggressive Lipid Lowering), and
SEARCH (Study of the Effectiveness of Additional
Reduction in Cholesterol and Homocysteine). From
these trials’ data, and using the latest Cochrane
methodology and focusing on outcomes that are most
relevant to patients, it was shown that high-intensity
statins had no effect on total mortality as compared
to standard dose statins (relative risk: 0.99; 95% con-
ﬁdence interval: 0.93 to 1.06). High-dose statins
increased withdrawals due to adverse effects (relative
risk: 1.45; 95% conﬁdence interval: 1.34 to 1.58;
